8-Cyclopentyltheophylline

8-Cyclopentyltheophylline

SCHEMBL431907

Cn1c(=O)c2[nH]c(C3CCCC3)nc2n(C)c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 5/20 1.00
ADORA2B P29275 5/20 1.00
ADORA3 P0DMS8 3/20 1.00
LMNA P02545 2/20 1.00
CYP1A2 P05177 2/20 1.00
PMP22 Q01453 2/20 1.00
MAPK1 P28482 2/20 1.00
CYP3A4 P08684 1/20 1.00
NFKB1 P19838 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
ADORA1 P30542 4/20 0.63
HIF1A Q16665 2/20 0.63
MEN1 O00255 1/20 0.63
GMNN O75496 1/20 0.63
TSHR P16473 1/20 0.63
KMT2A Q03164 1/20 0.63
ALOX15 P16050 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
8-Cyclopentyltheophylline SCHEMBL13397811 1.00 ADORA2A (1.00) ADORA2AADORA2BADORA3LMNACYP1A2
SCHEMBL515967 0.98 ADORA2A (1.00) ADORA2AADORA2BADORA3LMNACYP1A2
SCHEMBL516001 0.94 ADORA2A (0.88) ADORA2AADORA2BADORA3LMNACYP1A2
SCHEMBL24559224 0.88 ADORA2A (0.79) ADORA2AADORA2BADORA3LMNACYP1A2
SCHEMBL9262515 0.85 ADORA2A (0.74) ADORA2AADORA2BADORA3LMNACYP1A2
SCHEMBL8356923 0.84 ADORA1 (0.85) ADORA2AADORA2BADORA3LMNACYP1A2
SCHEMBL14903087 0.84 ADORA1 (0.85) ADORA2AADORA2BADORA3LMNACYP1A2
SCHEMBL10675625 0.82 ADORA2A (0.69) ADORA2AADORA2BADORA3LMNACYP1A2
SCHEMBL10670203 0.82 ADORA2A (0.69) ADORA2AADORA2BADORA3LMNACYP1A2
8-Cyclopentyltheophylline SCHEMBL6742249 0.81 ADORA2A (0.66) ADORA2AADORA2BADORA3LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 580 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739300-A1 MODULATORS OF IRON METABOLISM FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION SORBONNE UNIVERSITE (FR) 2026-05-13 EP claimed
EP-4426280-B1 PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS GURBA ALEXANDRE (CH) 2026-03-18 EP claimed
EP-4648778-A1 METHOD FOR TREATING NETOSIS-MEDIATED DISEASES National Health Research Institutes (TW) 2025-11-19 EP claimed
US-20250057791-A1 PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS GURBA ALEXANDRE (CH) 2025-02-20 US claimed
WO-2025012154-A1 MODULATORS OF IRON METABOLISM FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION SORBONNE UNIVERSITE (FR) 2025-01-16 WO claimed
WO-2025012668-A1 MODULATORS OF IRON METABOLISM FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION SORBONNE UNIVERSITE (FR) 2025-01-16 WO claimed
EP-4426280-A1 PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS Gurba, Alexandre (CH) 2024-09-11 EP claimed
WO-2024151651-A1 METHOD FOR TREATING NETOSIS-MEDIATED DISEASES NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2024-07-18 WO claimed
WO-2023111938-A1 PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS GURBA, Alexandre (CH) 2023-06-22 WO claimed
EP-4197533-A1 PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS Guerin, Patrick (CH) 2023-06-21 EP claimed
US-5248678-A Administering adenosine receptor antagonist and a GABA antagonist FRACTAL LABORATORIES, INC. (US) 1993-09-28 US claimed
US-5192740-A Adenosine receptor antagonist UNIVERSITY OF ALBERTA (CA) 1993-03-09 US claimed
EP-0167566-A4 ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. SUNSHINE ABRAHAM (US) 1987-06-29 EP claimed
EP-0165308-A4 ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. RICHARDSON VICKS INC (US) 1986-05-16 EP claimed
US-4567183-A SYNERGISTIC, POTENTIATION ANALGESIC ASSOCIATES (US) 1986-01-28 US claimed
EP-0167566-A1 ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME SUNSHINE, Abraham (US) 1986-01-15 EP claimed
EP-0165308-A1 ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME. RICHARDSON VICKS INC (US) 1985-12-27 EP claimed
US-4558051-A Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same RICHARDSON-VICKS, INC. (US) 1985-12-10 US claimed
WO-1985002540-A1 ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME RICHARDSON-VICKS, INC. (US) 1985-06-20 WO claimed
WO-1985002542-A1 ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS COMPRISING XANTHINES AND METHODS OF USING SAME SUNSHINE ABRAHAM 1985-06-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250057791-A1 PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS P2RX2, P2RX3, P2RX1 ADORA2A 18/4885ADORA2B 21/4885ADORA3 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.